Olema Pharmaceuticals(NASDAQ) OLMA

Olema Pharmaceuticals, Inc. makes medicines for women with breast cancer. These treatments help patients when other therapies stop working. The company focuses on stopping cancer from growing and spreading.

Fighting Cancer With Targeted Science

• Palazestrant: Oral drug candidate designed to block and break down receptors that fuel cancer growth.
• OP-3136: Experimental treatment targeting the KAT6 protein to stop tumors in multiple cancer types.
• Combination Programs: Clinical trials testing company drugs with existing therapies to overcome treatment resistance in advanced patients.

Strategic Partnerships and Clinical Steps

• Initiated the OPERA-01 Phase 3 clinical trial in November 2023.
• Announced a drug supply agreement with Novartis in December 2024.
• Completed a private placement for $237.0 million in net proceeds in late 2024.
• Partnered with Bayer in May 2026 to study combination treatments for prostate cancer.

What Makes Olema Different?

Olema uses a dual-action approach that both blocks and degrades estrogen receptors to treat resistant cancers. The company relies on third-party partners for all manufacturing and clinical trial execution to focus on drug discovery.

A Look at the Finances

• Research and development expenses were $107.0 million for the six months ended June 30, 2026, up 44% year over year.
• Net loss was $116.3 million for the six months ended June 30, 2026, up 57% year over year.
• Cash, cash equivalents, and marketable securities totaled $461.1 million as of June 30, 2026.
• Net proceeds from common stock sales through an at-the-market offering were $41.9 million for the six months ended June 30, 2026.
• Accumulated deficit reached $713.8 million at the end of the second quarter of 2026.

Bottom Line

Olema has progressed from early research to late-stage clinical development of targeted oncology therapies. Its partnerships with major pharmaceutical firms and focus on treatment resistance define its current operational path.